glp-1 agonists drugs How Receptor Evolved from Diabetes to Weight Loss Treatments GLP-1 Receptor Agonists and Research
Description
The mean LVEF was 33.7% and 35.4% in the liraglutide and placebo groups, respectively, and 60% of patients had ischaemic heart disease
She added that most cases of nausea, vomiting and diarrhea occurred during dose escalation in the first 24 weeks of the study
FDA approval dates for these GLP-1 RAs are detailed in Table S3
Lancet 373, 21252135
Participants were also assessed at weeks 52 and 78 to assess durability of glucose lowering with the two treatment approaches
